Capecitabine as adjuvant treatment for stage III colon cancer.
By C. Twelves, A. Wong, M. Nowacki, M. Abt, H. Burris, A. Carrato, J. Cassidy, A. Cervantes, J. Fagerberg, V. Georgoulias and 16 more. New England Journal of Medicine, 2005
1,201 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/e0730cbe1d39cda5a06b49c14e2cdb496065f9eb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. (2008, methodology): “Capecitabine (Xeloda; Hoffmann-La Roche Inc, Nutley, NJ) is an oral fluoropyrimidine with similar efficacy to bolus FU/FA as first-line treatment for MCRC(2-4) and as adjuvant therapy for stage III colon cancer.(5) Capecitabine has been tested in combination with oxaliplatin in a variety of differen”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “Subsequently, in domestic and international randomized controlled trials, the non‐inferiority of Cape (X‐ACT [302]) and UFT + LV (NSABP C‐06 [303], JCOG 0205 [144]) to 5‐FU + l‐LV was shown, followed by the non‐ inferiority of S‐1 to UFT + LV (ACTS‐CC [145]).”
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, result): “3 years of follow-up, the data still confirm the equivalence in terms of DFS between capecitabine and 5-FU/LV [33] in stage III patients.”